Island Pharmaceuticals (ASX:ILA) has strengthened its financial position, announcing that directors and substantial shareholders have exercised more than 14.4 million options, delivering just over $1 million in new capital to support the company’s antiviral development programs.
Island Pharmaceuticals secures boost as directors and major shareholders exercise options
December 3, 2025 Australian Biotech
Latest Video
New Stories
-
Medtech pipeline accelerates as report showcases translation success of MTPConnect-backed innovators
December 3, 2025 - - Australian Biotech -
CEO pay rebounds across ASX health and biotech as boards balance pressure and retention
December 3, 2025 - - Australian Biotech -
Melbourne scientists discover how electrical pulses could transform tissue and organ regeneration
December 3, 2025 - - Australian Biotech -
Island Pharmaceuticals secures boost as directors and major shareholders exercise options
December 3, 2025 - - Australian Biotech -
BCAL launches national registry to track real-world impact of BREASTESTplus
December 3, 2025 - - Australian Biotech -
Noxopharm advances autoimmune candidate as first multiple-dose cohort clears safety review
December 3, 2025 - - Australian Biotech -
Cost of multiple sclerosis in Australia surges as prevalence accelerates
December 3, 2025 - - Latest News
